Special drug-use survey of Tarlige tablet (evaluation of safety in long-term use)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031200212

Enrollment

900

Registered

2020-11-30

Start date

2020-10-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral neuropathic pain

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with peripheral neuropathic pain not treated with Tarlige tablet before (2) Ambulatory outpatients who were able to visit the clinic unassisted (3) Patients who will continue to administration of Tarlige tablet at the return visit after started of administration (including the start date, 28 days or less) (4) Patients who started administration of Tarlige tablet during the contract period (contract period based on the contract with each medical site) (5) Patients who started administration of Tarlige tablet during the registration period (6) Patients from whom written informed consent was obtained

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Incidence of onset of diabetes mellitus Incidence of aggravated diabetes mellitus Incidence of visual disturbance	—

Secondary

Measure	Time frame
Incidence of hypoglycemia	—

Contacts

Public ContactGPSP Contact

Daiichi Sankyo Co.,Ltd.

contact_gpsp@daiichisankyo.co.jp+81-3-6225-1059

Outcome results